A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular...

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Rosacea is a common inflammatory skin condition with unclear pathogenesis and no definitive cure.
• Current rosacea therapies primarily focus on reducing inflammation.

Purpose of the Study:

• To evaluate the efficacy, tolerability, and safety of 1% pimecrolimus cream for rosacea treatment.
• To compare pimecrolimus cream against a placebo in a split-face trial.

Main Methods:

• A randomized, single-blinded, placebo-controlled, split-face trial involving 25 patients with papulopustular rosacea.
• Patients applied 1% pimecrolimus cream to one hemi-face and placebo cream to the other, twice daily for 4 weeks.
• Clinical and subjective assessments, including rosacea severity scores for erythema, papules, pustules, edema, and telangiectasia, were recorded at baseline and follow-up visits.

Main Results:

• Twenty-four patients completed the study with good compliance and safety.
• Pimecrolimus cream showed a statistically significant improvement in erythema and total rosacea severity score at week 2 (P=0.01 and P=0.03, respectively).
• Subjective symptom improvement was reported by 54.16% of patients using pimecrolimus versus 12.50% using placebo, though not statistically significant (P=0.15).

Conclusions:

• Pimecrolimus cream demonstrated efficacy primarily for erythema reduction in rosacea.
• It may serve as a treatment option for rosacea patients with significant erythema requiring prompt improvement.
• Further research with larger cohorts and diverse rosacea subtypes is recommended to fully elucidate pimecrolimus's therapeutic potential.